Journal articleDrug Dev Res2018
Actinomycin-D and dimethylamino-parthenolide synergism in treating human pancreatic cancer cells.
- Journal
- Drug Dev Res
- Published
- 17 September 2018
- Citations
- 24
- Type
- Article
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract license unknown
Preclinical Research & Development Pancreatic cancer is the third leading cause of death in the US with a poor 5-year survival rate of 8.5%. A novel anti-cancer drug, dimethylamino parthenolide (DMAPT), is the water-soluble analog of the natural sesquiterpene lactone, parthenolide. … Excerpt only: this text is the publisher’s. Read it in full at the source.